LT3697405T - Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti - Google Patents

Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti

Info

Publication number
LT3697405T
LT3697405T LTEPPCT/EP2018/078335T LTEP2018078335T LT3697405T LT 3697405 T LT3697405 T LT 3697405T LT EP2018078335 T LTEP2018078335 T LT EP2018078335T LT 3697405 T LT3697405 T LT 3697405T
Authority
LT
Lithuania
Prior art keywords
viral
bacterial infections
mek inhibitor
new mek
new
Prior art date
Application number
LTEPPCT/EP2018/078335T
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of LT3697405T publication Critical patent/LT3697405T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEPPCT/EP2018/078335T 2017-10-17 2018-10-17 Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti LT3697405T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
LT3697405T true LT3697405T (lt) 2021-10-25

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/078335T LT3697405T (lt) 2017-10-17 2018-10-17 Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti

Country Status (20)

Country Link
US (2) US11903917B2 (lt)
EP (2) EP3697405B1 (lt)
JP (3) JP7227967B2 (lt)
KR (1) KR102848960B1 (lt)
CN (2) CN111479566B (lt)
AU (2) AU2018351475A1 (lt)
CA (1) CA3078424A1 (lt)
CY (1) CY1124507T1 (lt)
DK (1) DK3697405T3 (lt)
EA (1) EA202090693A1 (lt)
ES (2) ES2883639T3 (lt)
HR (1) HRP20211252T1 (lt)
HU (1) HUE055738T2 (lt)
LT (1) LT3697405T (lt)
MX (2) MX2020003473A (lt)
PL (1) PL3697405T3 (lt)
PT (1) PT3697405T (lt)
SI (1) SI3697405T1 (lt)
WO (1) WO2019076947A1 (lt)
ZA (1) ZA202002069B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
US20220370384A1 (en) 2019-08-27 2022-11-24 Atriva Therapeutics Gmbh Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
EP4041212B1 (en) 2019-10-08 2025-07-23 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
ES2995196T3 (en) * 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2002534381A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた抗ウィルス法
HUP0202623A3 (en) 1999-07-16 2003-03-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DE10300222A1 (de) 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
ES2575995T3 (es) * 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
CN109276716B (zh) 2012-10-08 2021-06-08 归属疗法有限公司 用在病毒性疾病的治疗中的mek抑制剂
EP3142658B1 (en) 2014-05-16 2020-01-15 Atriva Therapeutics GmbH Novel anti-infective strategy against influenza virus and s. aureus coinfections
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
EP4041212B1 (en) 2019-10-08 2025-07-23 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
ES2995196T3 (en) 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
WO2019076947A1 (en) 2019-04-25
MX2022016066A (es) 2023-02-02
SI3697405T1 (sl) 2021-11-30
BR112020007442A2 (pt) 2020-10-27
PL3697405T3 (pl) 2021-12-13
AU2024205853A1 (en) 2024-09-05
EP3697405A1 (en) 2020-08-26
AU2024205853B2 (en) 2026-08-06
EP3973960C0 (en) 2025-09-03
CY1124507T1 (el) 2022-07-22
PT3697405T (pt) 2021-08-27
ZA202002069B (en) 2021-10-27
KR102848960B1 (ko) 2025-08-21
JP7618276B2 (ja) 2025-01-21
JP7227967B2 (ja) 2023-02-22
CN118141795A (zh) 2024-06-07
KR20200072499A (ko) 2020-06-22
HRP20211252T1 (hr) 2021-11-12
CN111479566A (zh) 2020-07-31
US20200289445A1 (en) 2020-09-17
ES3041322T3 (en) 2025-11-11
EP3697405B1 (en) 2021-07-14
JP2020537659A (ja) 2020-12-24
US11903917B2 (en) 2024-02-20
JP2025031917A (ja) 2025-03-07
HUE055738T2 (hu) 2021-12-28
EP3973960A1 (en) 2022-03-30
EA202090693A1 (ru) 2020-10-19
EP3973960B1 (en) 2025-09-03
JP2023058631A (ja) 2023-04-25
ES2883639T3 (es) 2021-12-09
CN111479566B (zh) 2024-05-07
MX2020003473A (es) 2020-10-01
AU2018351475A1 (en) 2020-04-30
CA3078424A1 (en) 2019-04-25
DK3697405T3 (da) 2021-08-23
US20240245637A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
DK3697405T3 (da) Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
IL262762A (en) Methods for diagnosis of bacterial and viral infections
LT3877376T (lt) Piridazinono junginiai ir jų panaudojimas
LT3630761T (lt) Kras g12c inhibitoriai ir jų naudojimo būdai
EP3711001A4 (en) K-BASED COMPLIANCE AND PREFERENCE SYSTEM
LT3429596T (lt) Cikliniai dinukleotidų junginiai ir panaudojimo būdai
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
EP3590577A4 (en) OBJECT TRACKING DEVICE
LT3578547T (lt) Sulfonilkarbamidai ir giminingi junginiai bei jų panaudojimas
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3687506T (lt) Pakeistieji benzofuranas, benzopirolas, benzotiofenas ir struktūriškai susiję komplemento inhibitoriai
IL278122B1 (en) Pteridinone compounds and uses thereof
FI20165583A (fi) Ilmastointijärjestelmä ja -menetelmä
DK3385377T3 (da) Bakteriemannanaser
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
LT3262037T (lt) Naujas chinolino darinys, skirtas panaudoti virusinių infekcijų gydymui ir prevencijai
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
LT3360862T (lt) Alkinilpiridinprolilhidroksilazės inhibitorius, ir jo gavimo būdas ir medicininis panaudojimas
LT3268374T (lt) Kv1.3 inhibitoriai ir jų medicininis pritaikymas
LT3337506T (lt) Deriniai ir jų panaudojimas
LT3630111T (lt) Junginiai ir būdai, skirti bakterinių infekcijų gydymui
EP3638297A4 (en) BACTERIAL VACCINE
EP3429517A4 (en) COOLING CHAIN AND DUST
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai